Zobrazeno 1 - 10
of 21
pro vyhledávání: '"M C Dubinsky"'
Autor:
M Chaparro, A Armuzzi, P M Irving, M Allez, M C Dubinsky, B E Sands, M Goetsch, W Wang, K Shan, J Woolcott, L Bartolome, K Wosik, R Panaccione
Publikováno v:
Journal of Crohn's and Colitis. 17:i107-i110
Background Patient-reported outcomes such as stool frequency (SF) and rectal bleeding (RB) are important measures of ulcerative colitis (UC) activity and treatment effect. Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-pho
Publikováno v:
Journal of Crohn's and Colitis. 17:i339-i342
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). This novel analysis evaluated tofacitinib outcomes using items from the Inflammatory Bowel Disease Questionnaire-32 (IBDQ) and Short
Autor:
S Travis, A P Bleakman, D Rubin, M C Dubinsky, R Panaccione, T Hibi, T H Gibble, C Kayhan, E Flynn, C Sapin, C Atkinson, S Schreiber, J Jones
Publikováno v:
Journal of the Canadian Association of Gastroenterology. 6:52-54
Background The Communicating Needs and Features of IBD Experiences (CONFIDE) study aims to increase understanding of the impact of symptoms on patients with moderate to severe UC and Crohn’s disease and to investigate gaps in communication with hea
Autor:
M C Dubinsky, G D’Haens, O Dewit, P Juillerat, R Panaccione, T Fujii, A P Lacerda, E Dubcenco, S Anyanwu, C Doshi, M Mallick, A Garrison, J Liu, E V Loftus Jr
Publikováno v:
Journal of Crohn's and Colitis. 17:i104-i106
Background Corticosteroids (CS) may be used for induction of remission in Crohn’s disease (CD); however, side effects, toxicities, and low rates of mucosal healing may limit their long-term use. Safety and efficacy of upadacitinib (UPA), an oral se
Autor:
S Vermeire, B E Sands, M C Dubinsky, B G Feagan, R Panaccione, V Jairath, A Yarur, M Chiorean, J Panés, M Goetsch, C J Rabbat, P Shah, J Wu, S Ghosh
Publikováno v:
Journal of Crohn's and Colitis. 17:i709-i711
Background Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of ulcerative colitis (UC). The ELEVATE UC 52 trial utilized a treat-through design w
Autor:
L Peyrin-Biroulet, M C Dubinsky, B E Sands, J Panés, S Schreiber, W Reinisch, B G Feagan, S Danese, A Yarur, G D’Haens, M Goetsch, K Wosik, J Wu, I Modesto, A McDonnell, L Bartolome, C J Rabbat, S Vermeire
Publikováno v:
Journal of Crohn's and Colitis. 17:i536-i538
Background Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). Although ≈30% of UC patie
Autor:
S Vermeire, A Yarur, D T Rubin, M C Dubinsky, M Regueiro, P Irving, L Peyrin-Biroulet, M Goetsch, G Gu, J Wu, I Modesto, A McDonnell, C J Rabbat, J Green, P Anthopoulos
Publikováno v:
Journal of Crohn's and Colitis. 17:i604-i606
Background Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). First-dose, transient heart
Publikováno v:
Journal of Crohn's and Colitis. 17:i515-i517
Background Transmural healing (TH) assessed by intestinal ultrasound (IUS) is associated with improved inflammatory bowel disease (IBD) outcomes. This study evaluates the relationship between ustekinumab trough levels (UTL) and sonographic TH in chil
Autor:
S Schreiber, A P Bleakman, M C Dubinsky, D Rubin, T Hibi, R Panaccione, T H Gibble, C Kayhan, E Flynn, C Sapin, C Atkinson, S Travis, J Jones
Publikováno v:
Journal of the Canadian Association of Gastroenterology. 6:35-36
Background Moderate to severe ulcerative colitis (UC) exerts a significant burden on patients’ lives. Patients with UC report that bowel urgency has a substantial negative impact on their quality of life and psychosocial functioning, however, this
Autor:
D B Clemow, C Sapin, T Hibi, M C Dubinsky, S Vermeire, S Schreiber, T H Gibble, L Peyrin-Biroulet, M Watanabe, R Panaccione, J Jones
Publikováno v:
Journal of the Canadian Association of Gastroenterology. 6:31-32
Background Ulcerative colitis (UC) can result in a high prevalence of bowel movement urgency (BU), significantly reducing patient quality of life. Purpose Early BU improvement association with later clinical endpoint improvements was examined in mode